GSK Canada & Pan-Canadian Pharmaceutical Alliance Sign LOI For Blenrep For A Type Of Multiple Myeloma

GSK•2026-09-22

Publicly funded access

GSK Canada said patients will gain publicly funded access to Blenrep as a treatment option for relapsed/refractory multiple myeloma.

Letter of intent for Blenrep

Sept. 22 (Reuters) - GSK Canada and the Pan-Canadian Pharmaceutical Alliance have signed a letter of intent for Blenrep for the treatment of relapsed or refractory multiple myeloma.

GSK Canada & Pan-Canadian Pharmaceutical Alliance Sign LOI For Blenrep For A Type Of Multiple Myeloma

Publicly funded access

Letter of intent for Blenrep

Related News

Cerenome signs in-network deal with Blue Cross Blue Shield of Michigan for CNSide test

Abivax SA <ABVX.O>: Truist Securities cuts target price to $151 from $155

Edgewise Therapeutics details preclinical profile of EDG-7500 cardiac sarcomere modulator in hypertrophic cardiomyopathy

Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia

SanDisk Corporation <SNDK.O>: Rosenblatt Securities initiates coverage with buy rating; price target $2400